Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (2358)	10/16/1997 10:36:00 PM
From: Oliver & Co	of 6136

Dear Margie: The rep for Rescriptor (Delavirdine), was in my office yesterday, he tells me that they are studying BID dosing. Also, something new, Rescriptor appears to double Nelfinavir levels. I think that all these combinations are really going to allow us to go to BID dosing faster. We had noticed drops to undetectable in all the patients we had placed on Rescr/Viracept (until now we had been told Rescriptor did not increase Viracept, and were not adjusting dose. Also, patients that I had to place in the powder form of Viracept(because they could not swallow the pills)are telling me that the diarrhea they had with the tabs is gone.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next